HAP1細胞およびがん関連細胞のカタログ細胞株は、皆様のご研究に役立ち、ご研究を促進するための理想的な研究ツールであると確信しています。

しかしながら、HAP1細胞およびがん関連細胞のカタログ細胞株の性能に満足できない場合は、テクニカルサポートまでご連絡ください。当社の販売条件に詳述されているように、問題を解決するためにお客様と熱心に協力します。

Limited use agreement

All cell line engineering projects are subject to our Terms & Conditions and our Limited Use Label License.

Knock-ins

Products that have utilized CRISPR Cas9 systems and methodologies to knock-in a gene, and their use, may be the subject of one or more of the following patents and applications controlled by Sigma-Aldrich Co. LLC (SIGMA): Patent applications and issued patents that entered their respective National Stage from PCT International Pub. No. WO 2014/089290, including, but not limited to, the following, and substitutions, divisions, continuations, continuations-in-part, reissues, re-examinations, and extensions thereof: Australia Patent Nos. 2013355214; 2017204031; and 2018229489; Canada Patent Nos. 2,891,347 and 2,977,152; China Patent No. CN105142669; European Patent Nos. EP 2 928 496 B1; EP 3 138 910 B1, 3 138 911 B1, EP 3 138 912 B1, EP 3 360 964 B1, EP 3 363 902 B1; Israel Patent No. IL238856; Singapore Patent No. 11201503824S; South Korea Patent Nos. 10-1844123 and 10-2006880; and U.S. Patent Nos. 10,731,181 and 10,745,716; and U.S. Application Serial Nos. 15/188,927; 15/188,931; and 15/456,204 (the “Patent Rights”).